Small Pharma Inc. (DMTTF)
| Previous Close | 0.1113 |
| Open | 0.1254 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.1118 - 0.1273 |
| 52 Week Range | 0.0450 - 0.1905 |
| Volume | |
| Avg. Volume | 81,938 |
| Market Cap | 40.935M |
| Beta (5Y Monthly) | 1.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0500 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NewsfileCybin to Acquire Small Pharma Inc.
- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy -- Combined portfolio creates the industry's largest, most advanced, well-protected deuterated DMT program -- Combination creates the largest intellectual property portfolio in the psychedelic drug development sector with 28 patents granted and 158 patents pend
GlobeNewswireSmall Pharma Reports Fiscal First Quarter 2024 Highlights
• Last patient dosed in SPL026-SSRI drug interaction study with data readout anticipated in Q3 2023 • Potential for an expedited route to an international, multi-site Phase II study with SPL028 in 2024, based on clinical findings across SPL026 and SPL028 programs to date • SPL026 Phase IIa clinical trial results well-received at several international scientific conferences • Anticipated cash runway to at least Q4 2024 following recent operational restructuring LONDON, July 27, 2023 (GLOBE NEWSWI
- GlobeNewswire
Small Pharma Announces SPL028 R&D Strategy Update
• Preliminary findings from ongoing Phase I trial of second-generation DMT asset SPL028 indicate the potential for a unique therapeutic profile • Proof-of-concept data from Company’s native DMT program, SPL026, offers potential for an expedited route to an international, multi-site Phase II study with SPL028 in 2024 • Implementation of ongoing operational efficiencies including a reduction in headcount of approximately one-third LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV:
